查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2002666

口服固體製劑契約製造市場：依劑型、治療領域、研發階段、應用及最終用戶分類－2026-2032年全球市場預測

Oral Solid Dosage Contract Manufacturing Market by Form Type, Therapeutic Area, Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年口服固體製劑的契約製造市場價值為 481 億美元，預計到 2026 年將成長至 523.9 億美元，年複合成長率為 9.13%，到 2032 年將達到 887 億美元。

主要市場統計數據
基準年 2025 481億美元
預計年份：2026年 523.9億美元
預測年份 2032 887億美元
複合年成長率 (%) 9.13%

簡明扼要、全面介紹當前影響口服固體製劑契約製造的趨勢及其對相關人員的策略意義。

口服固體製劑契約製造產業處於醫藥創新、複雜供應鏈和嚴格管理體制的交匯點，要求相關人員在敏捷性和卓越品質之間取得平衡。本執行摘要概述了影響生產力計畫、製劑策略和合作夥伴選擇的結構性因素，重點關注上市速度與長期業務永續營運之間的競爭關係，從而整體情況了該行業。隨著開發平臺的擴展和客戶需求的多樣化，契約製造製造商正從單純的生產合作夥伴轉變為提供製劑專業知識、法規知識和生命週期管理支援的策略夥伴。

分析技術、法規和供應鏈的變革性變化，這些變化正在重新定義契約製造中的生產能力、品質期望和夥伴關係模式。

口服固體製劑的契約製造產業正經歷一系列變革，這些變革的驅動力來自技術進步、監管要求以及不斷變化的客戶需求。連續生產和先進的製程控制系統正從試點階段走向成熟，最終成為檢驗的生產路線，從而提高了生產效率並加強了對關鍵品質屬性的控制。同時，生產營運的數位化，包括電子批次記錄、預測性維護和進階分析，正在重塑產能監控、偏差管理和監管證據收集的方式。這些技術進步正在催生新的夥伴關係模式，製造商不再僅僅提供單一批次的生產服務，而是提供整合的開發和規模化服務。

評估 2025 年美國關稅政策變化對採購、成本結構、供應鏈韌性和策略採購選擇的累積影響。

美國推出的2025年關稅政策對口服固體製劑契約製造的採購選擇、單位成本結構和緊急時應對計畫產生了多方面的影響。關稅調整影響了中間輔料、活性藥物成分和某些資本設備的進口成本競爭力，促使許多製造商及其客戶重新評估供應商選擇和庫存策略。一些企業正在採取即時措施來降低跨境成本波動帶來的風險，例如採購管道多元化、建立關鍵原料的庫存緩衝以及評估近岸外包和回岸外包的替代方案。然而，這些戰術性措施需要在營運成本密集度和供應鏈柔軟性之間做出權衡。

細分市場的洞察揭示了劑型、治療領域、應用、開發階段和客戶類型如何影響契約製造業務的服務需求。

了解細分市場的發展趨勢對於理解口服固體製劑契約製造的需求促進因素和產能要求至關重要。當劑型是首要考慮因素時，與片劑相比，膠囊在供應鏈和生產設施方面有著獨特的要求。膠囊分為硬膠囊和軟膠囊；顆粒劑需要考慮速釋和緩釋；丸劑需要包衣丸劑和多顆粒製劑方面的專業知識；片劑則根據是否包衣而採用不同的生產方法。這些劑型特有的因素決定了資本投資、分析測試的範圍和穩定性測試方案的複雜性，以及哪些供應商適合進行研發工作，哪些供應商更適合大規模商業化生產營運。

區域戰略展望：美洲、歐洲、中東和非洲以及亞太地區的趨勢如何重塑製造地、物流和監管應對措施

區域趨勢差異顯著，影響製造商在製造地、監管策略和物流方面的策略選擇。在美洲，製造商受益接近性大規模商業市場和響應迅速的分銷網路，同時也面臨著嚴格的監管審查和激烈的競爭壓力，這些壓力要求某些產品類型的生產本地化。該地區通常是後期商業供應鏈和項目的首選之地，因為在這些項目中，產品上市時間和快速補貨能力至關重要，從而支持那些檢驗的大規模生產能力和先進品質系統的商業模式。

競爭資訊概述了領先的契約製造的策略重點、產能投資和夥伴關係方式。

領先的契約製造透過整合先進的技術能力、一體化的開發服務以及卓越的合規記錄來脫穎而出。頂級供應商會選擇性地投資於檢驗於多種固態製劑形式的靈活生產平台，同時維持嚴格的資料完整性和品質保證系統。他們通常會將生產能力投資與配方最佳化、分析方法開發和穩定性測試等輔助服務相結合，使客戶能夠順利地從臨床批次過渡到商業化生產，而無需重複的供應商交接。

為行業領導者提供切實可行的建議，以增強韌性、提高效率、抓住新機遇，並使其營運適應不斷變化的客戶和監管要求。

行業領導者可以透過制定一系列重點明確的營運和商業優先事項，將洞察轉化為實際行動。首先，投資於模組化、靈活的生產平台，該平台支援膠囊、顆粒、丸劑和片劑生產之間的快速切換，同時保持檢驗的品管。這種方法降低了進入不同項目的門檻，並加快了對不斷變化的客戶需求的反應速度。同時，加強製劑開發和分析服務，以應對複雜的治療領域，從低劑量中樞神經系統 (CNS) 產品到需要特殊隔離和穩定性通訊協定的腫瘤製劑。這些能力可以縮短規模化生產時間，並增強您作為長期夥伴關係夥伴的吸引力。

一套完善的調查方法，詳細說明了主要和次要數據的收集、專家檢驗、品管以及用於確保嚴謹見解和可重複性的分析框架。

本執行摘要的研究途徑整合了多個資料流和檢驗通訊協定，以確保分析的嚴謹性和可操作性。主要研究包括對契約製造及其基本客群中的技術負責人、品質主管、供應鏈經理和業務拓展主管進行結構化訪談。這些訪談提供了關於產能投資、商業重點以及監管和貿易趨勢對營運影響的第一手觀點。次要研究利用了公開的監管指南、專利申請、臨床試驗註冊資訊和開放原始碼企業資訊披露，以闡明觀察到的趨勢並識別產能部署的變化。

全面概述了口服固體製劑生產中面臨的戰略挑戰、風險因素以及投資和營運調整的優先領域。

本概要重點闡述了固態製劑契約製造領域相關人員面臨的幾項關鍵通用挑戰。技術差異化、營運柔軟性和供應鏈韌性將成為決定哪些供應商能夠贏得策略合約以及哪些客戶能夠確保可靠供應的關鍵因素。隨著連續生產、數位化品質系統和先進製劑開發能力從早期採用者走向行業標準，契約製造製造商的價值提案將取決於其能否將這些能力整合到一個統一的、面向客戶的服務模式中。監管對可追溯性和即時品質保證的要求進一步提升了這項策略需求，因此必須投資於能夠支援合規性和營運改善的數據系統。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：口服固體製劑的契約製造市場（以劑型分類）

  • 膠囊
    • 硬明膠
    • 軟明膠
  • 顆粒
    • 立即發布
    • 緩釋
  • 顆粒
    • 包衣顆粒
    • 多顆粒配方
  • 藥片
    • 包衣片
    • 無塗層

第9章：口服固體製劑的契約製造市場：依治療領域分類

  • 感染疾病物
    • 抗生素
    • 抗病毒藥物
  • 循環系統
    • 高血脂症
    • 高血壓
  • 中樞神經系統
    • 憂鬱症
    • 癲癇
  • 消化器官系統
    • 抑酸劑
    • 胃腸動力促效劑
  • 腫瘤學
    • 血液疾病
    • 固態腫瘤

第10章：口服固體製劑的契約製造市場：依階段分類

  • 臨床試驗
  • 商業的

第11章：口服固體製劑的契約製造市場：依應用領域分類

  • 非處方藥
  • 處方藥

第12章：口服固體製劑的契約製造市場：依最終用戶分類

  • 生物技術
  • 營養保健品
  • 製藥

第13章：口服固體製劑契約製造市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：口服固體製劑的契約製造市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：口服固體製劑契約製造市場：依國家口服固體製劑

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國口服固體製劑契約製造市場

第17章：中國口服固體製劑契約製造市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Ajinomoto Bio-Pharma Services, LLC
  • Almac Group Ltd.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • CordenPharma International GmbH
  • Curia Global, Inc.
  • Evonik Industries AG
  • Fareva SA
  • Hetero Drugs Limited
  • Jubilant Pharmova Limited
  • Lonza Group AG
  • PCI Pharma Services, Inc.
  • Piramal Pharma Limited
  • Recipharm AB
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-0D217D5AE60A

The Oral Solid Dosage Contract Manufacturing Market was valued at USD 48.10 billion in 2025 and is projected to grow to USD 52.39 billion in 2026, with a CAGR of 9.13%, reaching USD 88.70 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 48.10 billion
Estimated Year [2026] USD 52.39 billion
Forecast Year [2032] USD 88.70 billion
CAGR (%) 9.13%

A concise but comprehensive introduction that frames the current dynamics shaping oral solid dosage contract manufacturing and strategic relevance to stakeholders

The oral solid dosage contract manufacturing sector sits at the intersection of pharmaceutical innovation, complex supply chains, and stringent regulatory regimes, requiring stakeholders to balance agility with uncompromising quality. This executive summary introduces the landscape by outlining the structural drivers that dictate capacity planning, formulation strategy, and partner selection, and by framing the competitive tensions between speed-to-market and long-term operational resilience. As development pipelines broaden and customer needs diversify, contract manufacturers are transitioning from pure production partners to strategic collaborators who contribute formulation expertise, regulatory know-how, and lifecycle management support.

Understanding the forces at play requires a clear view of how product form and therapeutic focus inform manufacturing complexity, how clinical and commercial stages alter demand patterns, and how customer types-ranging from biotechnology innovators to established pharmaceutical companies and nutraceutical producers-shape service expectations. This introduction establishes the analytical lens used throughout the report: one that integrates technical capability assessment with commercial strategy and supply chain risk management. It also highlights the imperative for decision-makers to adopt an evidence-based approach to outsourcing that weighs the benefits of specialization against the vulnerabilities introduced by concentrated supplier networks and evolving trade policies. The remainder of this executive summary translates these observations into actionable insights for procurement, operations, regulatory affairs, and business development leaders.

An analysis of transformative technological, regulatory, and supply chain shifts redefining capacity, quality expectations, and partnership models in contract manufacturing

The contract manufacturing landscape for oral solid dosage forms is undergoing a series of transformative shifts driven by converging technological advances, regulatory expectations, and changing client demands. Continuous manufacturing and advanced process control systems are maturing from pilot demonstrations into validated production routes, enabling improved throughput and tighter control of critical quality attributes. At the same time, digitalization of manufacturing operations-covering electronic batch records, predictive maintenance, and advanced analytics-reshapes how capacity is monitored, deviations are managed, and regulatory evidence is compiled. These technology-enabled improvements are leading to new partnership models in which manufacturers offer integrated development and scale-up services rather than discrete batch production slots.

Regulatory frameworks are also evolving, with agencies prioritizing real-time product quality assurance and lifecycle data that demonstrate robustness and traceability. This regulatory emphasis increases the value of integrated data ecosystems and strengthens the negotiating position of manufacturers that can demonstrate end-to-end quality controls. Moreover, the rise of complex formulations and multiparticulate technologies adds technical differentiation to service offerings, pushing contract manufacturers to invest selectively in specialized capabilities. Concurrently, customer expectations are shifting: biotechnology firms seek nimble, development-focused partners; large pharmaceutical companies prioritize long-term, compliant suppliers with proven global distribution capabilities; and nutraceutical customers emphasize cost efficiency and rapid market access. The interaction of these factors is prompting a redefinition of what it means to be a strategic contract manufacturing partner and is accelerating consolidation, capability specialization, and collaborative commercialization models.

An assessment of the cumulative effects of United States tariff policy changes in 2025 on sourcing, cost structures, supply chain resilience, and strategic sourcing choices

The 2025 tariff environment introduced by the United States has produced layered implications across sourcing choices, unit cost structures, and contingency planning for contract manufacturing of oral solid dosage forms. Tariff adjustments have affected the cost competitiveness of importing intermediate excipients, active pharmaceutical ingredients, and certain capital equipment, prompting many manufacturers and their customers to reassess supplier footprints and inventory strategies. For some organizations, the immediate response has been to diversify procurement channels, build inventory cushions for critical raw materials, and evaluate nearshoring or reshoring alternatives to reduce exposure to cross-border cost volatility. These tactical moves, however, entail trade-offs between working capital intensity and supply chain flexibility.

Beyond procurement, tariff-induced input cost variability is influencing upstream decisions in formulation development and process selection. Teams are increasingly favoring formulations and excipient sets that minimize exposure to tariff-sensitive components or that permit substitution without compromising stability or performance. In parallel, contract manufacturers are investing in supply chain mapping and dual-sourcing strategies to mitigate single-point-of-failure risks. The tariffs also elevate the strategic importance of logistics optimization, classification accuracy, and free trade zone utilization as levers to manage landed costs. Looking forward, operational resilience will depend less on single cost advantages and more on the ability to integrate procurement agility, regulatory compliance for material substitutions, and transparent supplier relationships into a coherent risk-mitigation posture.

Segment-driven insights revealing how form, therapeutic focus, application, development stage, and customer type influence service demands across contract manufacturing operations

Segment-level dynamics are central to understanding demand drivers and capability requirements across oral solid dosage contract manufacturing. When form type considerations are front and center, capsules present distinct supply chain and tooling requirements compared to tablets; capsules can be segmented into hard gelatin and soft gelatin variants, while granules carry immediate release and modified release considerations, pellets require coated pellet or multiparticulate expertise, and tablets demand differentiated approaches for coated and uncoated configurations. These form-specific factors determine equipment investments, analytical testing scope, and stability program complexity, and they influence which providers are suited to development versus high-volume commercial work.

Therapeutic area focus further shapes service profiles, with anti-infective programs spanning antibiotics and antivirals that often emphasize rapid scale-up and stringent potency controls, and cardiovascular portfolios addressing hyperlipidemia and hypertension with long-term release and high-stability demands. Central nervous system therapies bring requirements for low-dose precision and controlled-release depression or epilepsy formulations, while gastrointestinal treatments such as acid reducers and prokinetics impose unique dissolution and biopharmaceutic considerations. Oncology work, whether hematological or solid tumor-directed, requires specialized containment, chain-of-custody processes, and patient-safety-focused quality systems. Application orientation-over-the-counter versus prescription-affects regulatory pathways, labeling, and shelf-life expectations, and the distinction between clinical trial-stage and commercial-stage projects determines the balance between flexibility and validated repeatability. Finally, customer type influences engagement models: biotechnology companies often require bespoke development support and agility, nutraceutical clients prioritize cost-efficient production and rapid time-to-shelf, and pharmaceutical customers emphasize long-term supply reliability and global regulatory harmonization. Taken together, these segmentation dimensions provide a framework for aligning technical investments, commercial positioning, and partnership design to client-specific needs.

Regional strategic outlook describing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics are reshaping manufacturing footprints, logistics, and regulatory navigation

Regional dynamics vary considerably and shape strategic choices for manufacturing footprint, regulatory strategy, and logistics. In the Americas, manufacturers benefit from proximity to large commercial markets and rapid-response distribution networks, but they also face stringent regulatory scrutiny and competitive pressure to localize production for certain product classes. This region is often chosen for late-stage commercial supply and for programs where time-to-market and rapid replenishment capabilities are critical, and it supports models that emphasize validated large-scale capacity and advanced quality systems.

Europe, Middle East & Africa present a multifaceted environment in which regulatory heterogeneity and fragmented pricing landscapes require sophisticated regulatory intelligence and flexible distribution planning. Manufacturers operating in this region must navigate diverse approval pathways, varying regulatory timelines, and regional trade agreements that influence where clinical and commercial batches are produced. Capability investments here often include modular facilities and robust pharmacovigilance infrastructures to support multinational launches and post-approval commitments.

Asia-Pacific remains a strategic hub for both development-stage work and volume manufacturing, offering extensive capabilities in formulation development, cost-competitive production, and rapidly expanding analytical and regulatory expertise. However, companies in this region must balance cost advantages with growing expectations around quality assurance, data integrity, and compliance with international regulatory standards. Supply chain resilience considerations, including port capacities and geopolitical risks, play a prominent role in regional sourcing decisions and in choices about inventory positioning for global programs.

Competitive intelligence summarizing the strategic priorities, capability investments, and partnership approaches that distinguish leading contract manufacturing organizations

Leading contract manufacturers distinguish themselves through a combination of deep technical capabilities, integrated development services, and demonstrated regulatory track records. Top-tier providers invest selectively in flexible production platforms that can be validated across a range of solid dosage forms while maintaining rigorous data integrity and quality assurance systems. They commonly pair capacity investments with adjacent services such as formulation optimization, analytical method development, and stability sciences, enabling clients to transition smoothly from clinical batches to commercial throughput without redundant vendor handoffs.

Another characteristic of high-performing firms is a clear articulation of partnership models that align incentives with client success. This includes transparent cost structures, shared risk arrangements for scale-up, and value-added services such as regulatory dossier support and serialization readiness. Investments in digital operations-real-time batch analytics, integrated quality management systems, and advanced supply chain visibility tools-also segregate leaders from commodity providers. Additionally, firms that cultivate robust supplier ecosystems for excipients, packaging, and specialized tooling are better positioned to manage disruptions and offer reliable lead times. Strategic M&A and alliance activity continue to be vehicles for capability expansion, but the most consequential competitive differentiators remain the ability to deliver predictable quality at scale, to innovate around formulation challenges, and to provide consultative support across product lifecycles.

Actionable recommendations for industry leaders to accelerate resilience, drive efficiency, capture new opportunities, and align operations with evolving customer and regulatory needs

Industry leaders can purposefully translate insight into action by adopting a set of targeted operational and commercial priorities. First, invest in modular, flexible manufacturing platforms that support rapid changeover between capsules, granules, pellets, and tablet production while preserving validated quality controls; this approach lowers barrier-to-entry for diverse programs and accelerates response to shifting client pipelines. Concurrently, strengthen formulation and analytical services to support complex therapeutic areas, from low-dose CNS products to oncology formulations requiring specialized containment and stability protocols. These capabilities reduce time-to-scale and increase the attractiveness of a provider for long-term partnerships.

Second, embed supply chain resilience into procurement and planning by instituting dual-sourcing strategies for critical excipients and leveraging near-term inventory strategies for tariff-sensitive inputs. Augment this with advanced procurement analytics and supplier performance monitoring to detect and remediate vulnerabilities early. Third, prioritize regulatory and data integrity investments that facilitate multinational submissions and real-time quality monitoring, including expanded capabilities for electronic batch records, serialization, and regulatory dossier compilation. Fourth, refine commercial offerings to include outcome-based partnership models and bundled development-to-commercial transition services that align incentives and reduce client friction. Finally, cultivate a digital transformation roadmap that links production analytics, predictive maintenance, and quality metrics to executive dashboards; this enables faster decision cycles, clearer capacity signaling, and demonstrable compliance during audits.

Robust research methodology detailing primary and secondary data collection, expert validation, quality controls, and analytical frameworks used to ensure rigorous insights and reproducibility

The research approach underpinning this executive summary integrates multiple data streams and validation protocols to ensure analytical rigor and practical relevance. Primary research included structured interviews with technical leaders, quality heads, supply chain managers, and business development executives across contract manufacturers and their customer base. These discussions provided first-hand perspectives on capability investments, commercial priorities, and the operational impacts of regulatory and trade developments. Secondary research drew on public regulatory guidance, patent filings, clinical trial registries, and open-source corporate disclosures to contextualize observed trends and identify shifts in capability footprints.

Data synthesis employed triangulation techniques that cross-checked qualitative insights with documented regulatory actions and observed capacity investments. Analytical frameworks included capability mapping, supply chain vulnerability assessment, and partner archetype development, which together enabled the translation of disparate signals into coherent strategic implications. Quality controls involved peer review by subject-matter experts, methodology audits to verify reproducibility of findings, and sensitivity checks to assess the robustness of conclusions against alternative interpretations. Throughout the research process, emphasis was placed on producing actionable intelligence that reflects operational realities and regulatory constraints while maintaining transparency about data sources and the inferential steps taken to derive recommendations.

Concluding synthesis that crystallizes strategic imperatives, risk considerations, and priority areas for investment and operational adaptation in oral solid dosage manufacturing

This executive synthesis highlights several convergent imperatives for stakeholders in oral solid dosage contract manufacturing. Technical differentiation, operational flexibility, and supply chain resilience will increasingly determine which providers win strategic engagements and which clients secure dependable supply. As continuous manufacturing, digital quality systems, and advanced formulation capabilities migrate from early adopters to industry norms, the value proposition of contract manufacturers will rest on the ability to integrate these capabilities into coherent, client-facing service models. Regulatory demands for traceability and real-time quality assurance add another layer of strategic necessity, requiring investment in data systems that support both compliance and operational improvement.

For decision-makers, the path forward requires balancing selective capital allocation with partnership innovation. Investing in modular production and adjacent development services builds optionality, while enhanced procurement strategies and geographic diversification mitigate tariff and logistics risks. Ultimately, organizations that combine technical excellence with consultative engagement-helping clients translate formulation science into scalable, regulatorily defensible production-will be best positioned to capture long-term partnerships. The insights in this summary aim to inform pragmatic next steps across procurement, operations, regulatory affairs, and business development, offering a roadmap for converting structural trends into competitive advantage and operational resilience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Solid Dosage Contract Manufacturing Market, by Form Type

  • 8.1. Capsules
    • 8.1.1. Hard Gelatin
    • 8.1.2. Soft Gelatin
  • 8.2. Granules
    • 8.2.1. Immediate Release
    • 8.2.2. Modified Release
  • 8.3. Pellets
    • 8.3.1. Coated Pellets
    • 8.3.2. Multiparticulate
  • 8.4. Tablets
    • 8.4.1. Coated
    • 8.4.2. Uncoated

9. Oral Solid Dosage Contract Manufacturing Market, by Therapeutic Area

  • 9.1. Anti Infectives
    • 9.1.1. Antibiotics
    • 9.1.2. Antivirals
  • 9.2. Cardiovascular
    • 9.2.1. Hyperlipidemia
    • 9.2.2. Hypertension
  • 9.3. Central Nervous System
    • 9.3.1. Depression
    • 9.3.2. Epilepsy
  • 9.4. Gastrointestinal
    • 9.4.1. Acid Reducers
    • 9.4.2. Prokinetics
  • 9.5. Oncology
    • 9.5.1. Hematological
    • 9.5.2. Solid Tumor

10. Oral Solid Dosage Contract Manufacturing Market, by Stage

  • 10.1. Clinical Trial
  • 10.2. Commercial

11. Oral Solid Dosage Contract Manufacturing Market, by Application

  • 11.1. Over The Counter
  • 11.2. Prescription Drugs

12. Oral Solid Dosage Contract Manufacturing Market, by End User

  • 12.1. Biotechnology
  • 12.2. Nutraceutical
  • 12.3. Pharmaceutical

13. Oral Solid Dosage Contract Manufacturing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oral Solid Dosage Contract Manufacturing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oral Solid Dosage Contract Manufacturing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Oral Solid Dosage Contract Manufacturing Market

17. China Oral Solid Dosage Contract Manufacturing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Ajinomoto Bio-Pharma Services, LLC
  • 18.6. Almac Group Ltd.
  • 18.7. Aurobindo Pharma Limited
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Catalent, Inc.
  • 18.10. CordenPharma International GmbH
  • 18.11. Curia Global, Inc.
  • 18.12. Evonik Industries AG
  • 18.13. Fareva SA
  • 18.14. Hetero Drugs Limited
  • 18.15. Jubilant Pharmova Limited
  • 18.16. Lonza Group AG
  • 18.17. PCI Pharma Services, Inc.
  • 18.18. Piramal Pharma Limited
  • 18.19. Recipharm AB
  • 18.20. Siegfried Holding AG
  • 18.21. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 258. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 259. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 262. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 263. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 264. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 265. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 266. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 268. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANU